 |
5 Diseases |  |
2 Trials |
|
2 Trials |  |
50 News |  |
- || Alenura (lidocaine/heparin) / Vaneltix
Trial completion date, Trial primary completion date: Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects with IC/BPS (clinicaltrials.gov) - Sep 20, 2024
P2, N=120, Recruiting, Sponsor: Vaneltix Pharma, Inc.
Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
- ||| Alenura (lidocaine/heparin) / Vaneltix
Enrollment open: Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects with IC/BPS (clinicaltrials.gov) - May 26, 2023
P2, N=120, Recruiting, Sponsor: Vaneltix Pharma, Inc.
Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025 Not yet recruiting --> Recruiting
- | Alenura (lidocaine/heparin) / Vaneltix
New P2 trial: Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects with IC/BPS (clinicaltrials.gov) - Feb 21, 2023
P2, N=120, Not yet recruiting, Sponsor: Vaneltix Pharma, Inc.
- Omeprazole RBX (omeprazole) / Generic Mfg.
AN INNOVATIVE TREATMENT APPROACH TO HEREDITARY ALPHA-TRYPTASEMIA AND INTERSTITIAL CYSTITIS (Monitor 2) - Nov 9, 2019 - Abstract #ACAAI2019ACAAI_825;
Pharmacotherapy, including omeprazole, hyoscyamine, cromolyn, methimazole, propranolol, sumatriptan, fexofenadine and oral prednisone incompletely improved her symptoms; she still had persistent abdominal cramping, dyspepsia, tachycardia, fatigue and headaches...She began bladder instillations for IC with heparin, lidocaine, sodium bicarbonate and sterile water, which improved her urinary symptoms and her headaches, abdominal cramping, fatigue, palpitations and exercise tolerance...β-tryptase is encoded by both TPSAB1 and TPSB2, while α-tryptase is only encoded by TPSAB1. Normally, α- and β-tryptase gene copies should add up to four; HAT occurs when there is an α-tryptase duplication and the summation of α-tryptase + β-tryptase is > 5.
- || lidocaine + heparin (URG101) / Urigen
Assisting a Cards inserting a Swann, I drew up, and gave him Heparin instead of Lidocaine for the insertion site (they came in the same size vials in our "kit"). I still think about that, and it's been 32 years. Pt did okay. RN me still not right with it... such a stupid mistake. (Twitter) - Nov 3, 2019
- | lidocaine + heparin (URG101) / Urigen, pentosan polysulfate sodium (PPS) / Paradigm Biopharma
Journal: Chronic scrotal pain: A variable symptom of interstitial cystitis/bladder pain syndrome. (Pubmed Central) - Aug 16, 2019
This scrotal pain may actually be referred pain from the bladder. Standard therapies for IC/BPS may be a treatment option for chronic idiopathic scrotal pain.
- | lidocaine/heparin (URG101) / Urigen
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (clinicaltrials.gov) - Jul 11, 2018
P2a, N=92, Terminated, Sponsor: Urigen
Standard therapies for IC/BPS may be a treatment option for chronic idiopathic scrotal pain. N=348 --> 92 | Trial completion date: Dec 2018 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018; Prematurely terminated based on interim study analysis
- || lidocaine/heparin (URG101) / Urigen
Trial completion date, Trial primary completion date: Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (clinicaltrials.gov) - May 4, 2018
P2a, N=348, Recruiting, Sponsor: Urigen
N=348 --> 92 | Trial completion date: Dec 2018 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018; Prematurely terminated based on interim study analysis Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- || lidocaine/heparin (URG101) / Urigen
Trial primary completion date: Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (clinicaltrials.gov) - May 4, 2017
P2a, N=348, Recruiting, Sponsor: Urigen
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2016 --> Dec 2017
- | lidocaine/heparin (URG101) / Urigen
Phase classification: Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (clinicaltrials.gov) - Jun 18, 2016
P2a, N=348, Recruiting, Sponsor: Urigen
Trial primary completion date: Dec 2016 --> Dec 2017 Phase classification: P2 --> P2a
- ||||| lidocaine/heparin (URG101) / Urigen
New P2 trial: Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (clinicaltrials.gov) - Oct 29, 2015
P2, N=348, Recruiting, Sponsor: Urigen